Table 2 Summarized patient characteristic of the included randomized trials
Study | Age | Male (%) | DM (%) | HP (%) | PreMI (%) | LVEF (%) | CPB duration (min) | Anesthetics | Baseline Serum Creatinine | β-blocker (%) | Statins (%) |
|---|---|---|---|---|---|---|---|---|---|---|---|
Balkanay 2015 I [17] | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
Balkanay 2015II [17] | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
Cho 2015 [12] | 63 | 48 | 19.5 | 45.5 | NA | 61.5 | 131 | Sevoflurane | 33 | NA | 63 |
DjaianiG 2016 [18] | 72.55 | 75.4 | 21.9 | 75.4 | 16.4 | NA | 98.99 | Isoflurane | 53 | 68.85 | 72.55 |
Leino 2011 [19] | 60.86 | 89.4 | NA | NA | NA | NA | NA | Isoflurane | NA | NA | 60.86 |
Li 2017 [14] | 67.18 | 69.1 | 32.3 | 63.2 | 9.8 | NA | 102.99 | Sevoflurane | 69.73 | 48.42 | 67.18 |
Liu 2016 [20] | 54.75 | 39.8 | 12.5 | 29.5 | NA | 65 | 71.15 | Sevoflurane | NA | NA | 54.75 |
Park 2014 [13] | 53.81 | 55.6 | 9.15 | 27.5 | NA | 61.87 | 166.75 | Sevoflurane | NA | NA | 53.81 |
Shehabi2009 [21] | 71.25 | 75.3 | 29.5 | 80.1 | 36.6 | NA | 98.98 | Sevoflurane | NA | NA | 71.25 |
Ammar 2016 [22] | 57.25 | 76 | 68 | 82 | NA | NA | 66.2 | Isoflurane | 94 | 56 | 57.25 |
Soliman 2016 [23] | 58.1 | 50 | 30.7 | 48.7 | 8.6 | 52.9 | NA | NA | 36.67 | NA | 58.1 |